Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.74 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.74 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.61 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30209188 | 0.91 | CRBN (0.62) | CRBNDDB1IKZF2GSPT1ALDH1A1 | |
| SCHEMBL20234722 | 0.91 | CRBN (0.71) | CRBNDDB1IKZF2GSPT1ALDH1A1 | |
| SCHEMBL24290234 | 0.89 | CRBN (0.70) | CRBNDDB1IKZF2GSPT1ALDH1A1 | |
| SCHEMBL27064563 | 0.88 | CRBN (0.60) | CRBNDDB1IKZF2GSPT1ALDH1A1 | |
| SCHEMBL29614655 | 0.87 | CRBN (0.70) | CRBNDDB1IKZF2GSPT1ALDH1A1 | |
| SCHEMBL21070167 | 0.87 | CRBN (0.70) | CRBNDDB1IKZF2GSPT1ALDH1A1 | |
| SCHEMBL22047520 | 0.87 | CRBN (0.70) | CRBNDDB1IKZF2GSPT1ALDH1A1 | |
| SCHEMBL23015894 | 0.87 | CRBN (0.66) | CRBNDDB1IKZF2GSPT1ALDH1A1 | |
| SCHEMBL23015944 | 0.87 | CRBN (0.66) | CRBNDDB1IKZF2GSPT1ALDH1A1 | |
| SCHEMBL20142905 | 0.87 | CRBN (0.66) | CRBNDDB1IKZF2GSPT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023115149-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2020081880-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| WO-2017184995-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | TP53, MCL1, LIMS1 | CRBN 1187/4885DDB1 55/4885IKZF2 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.